Format

Send to

Choose Destination
Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a009209. doi: 10.1101/cshperspect.a009209.

MET: a critical player in tumorigenesis and therapeutic target.

Author information

1
Molecular Oncology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.

Abstract

Since its discovery more than 25 years ago, numerous studies have established that the MET receptor is unique among tyrosine kinases. Signaling through MET is necessary for normal development and for the progression of a wide range of human cancers. MET activation has been shown to drive numerous signaling pathways; however, it is not clear how MET signaling mediates diverse cellular responses such as motility, invasion, growth, and angiogenesis. Great strides have been made in understanding the pleotropic aspects of MET signaling using three-dimensional molecular structures, cell culture systems, human tumors, and animal models. These combined approaches have driven the development of MET-targeted therapeutics that have shown promising results in the clinic. Here we examine the unique features of MET and hepatocyte growth factor/scatter factor (HGF/SF) structure and signaling, mutational activation, genetic mouse models of MET and HGF/SF, and MET-targeted therapeutics.

PMID:
23818496
PMCID:
PMC3685898
DOI:
10.1101/cshperspect.a009209
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center